GMAB vs. MRK: Genmab vs. Merck Stock Comparison
How do Genmab (GMAB) and Merck (MRK) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Genmab (GMAB) and Merck (MRK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while MRK is classified in Pharmaceuticals.
Merck (MRK) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | GMAB | MRK |
|---|---|---|
| Name | Genmab A/S American Depositary Shares | Merck & Co., Inc. |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 32.98 billion USD | 361.73 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2009 | January 2, 1962 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GMAB | MRK |
|---|---|---|
| Total Return (1Y) | 91.17% | 76.14% |
| Total Return (3Y, Annualized) | 20.70% | 16.48% |
| Total Return (5Y, Annualized) | 3.98% | 15.77% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GMAB | MRK |
|---|---|---|
| Volatility (1Y, Annualized) | 45.68% | 30.24% |
| Beta (5Y) | 0.72 | 0.11 |
| Max Drawdown (5Y) | -61.79% | -43.44% |
| Avg. Volume (3M) | 4.09M | 10.24M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GMAB | MRK |
|---|---|---|
| Sharpe Ratio (1Y) | 1.90 | 2.38 |
| Sortino Ratio (1Y) | 3.82 | 4.33 |
Profitability
ROE (TTM)
Genmab (GMAB) at 12.07% sits in the top ROE quartile, while Merck (MRK) at 5.06% is closer to the peer norm — stronger capital efficiency for GMAB.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.06%
- Max
- 109.18%
- Q3
- 6.23%
- MRK
- 5.06%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Genmab (GMAB) at 16.97% retains a top-quartile share of revenue as profit, ahead of Merck (MRK) at 3.64%, which keeps about the industry-typical share.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.64%
- Max
- 18.05%
- Q3
- 4.78%
- MRK
- 3.64%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Genmab (GMAB) at 37.15% and Merck (MRK) at 35.22% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.22%
- Max
- 83.12%
- MRK
- 35.22%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GMAB | MRK |
|---|---|---|
| ROE (TTM) | 12.07% | 5.06% |
| ROA (TTM) | 8.24% | 11.29% |
| Net Margin (TTM) | 16.97% | 3.64% |
| Operating Margin (TTM) | 37.15% | 35.22% |
| Gross Margin (TTM) | 92.67% | 75.20% |
Growth
Revenue Growth
Both Genmab (GMAB) at 19.19% and Merck (MRK) at 1.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Genmab (GMAB) at -9.23% and Merck (MRK) at 8.01% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | GMAB | MRK |
|---|---|---|
| Revenue Growth (YoY) | 19.19% | 1.31% |
| Revenue Growth (3Y CAGR) | 21.23% | 3.12% |
| EPS Growth (YoY) | -9.23% | 8.01% |
| EPS Growth (3Y CAGR) | 8.48% | 8.43% |
Financial Strength
Current Ratio (MRQ)
Both Genmab (GMAB) at 2.45 and Merck (MRK) at 1.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRK
- 1.35
- Min
- 0.10
Debt / Equity (MRQ)
Both Genmab (GMAB) at 0.82 and Merck (MRK) at 1.20 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.20
- Max
- 1.42
- MRK
- 1.20
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GMAB | MRK |
|---|---|---|
| Current Ratio (MRQ) | 2.45 | 1.35 |
| Debt / Equity (MRQ) | 0.82 | 1.20 |
| Net Debt / EBITDA | 2.45 | 1.50 |
Dividends
Dividend Yield (TTM)
Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Merck (MRK) reports a yield of 2.29%, ranking against industry peers normally.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.29%
- MRK
- 2.29%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Merck (MRK) reports payout ratio above 100% at 343.43%, meaning dividends exceeded current-period earnings; Genmab (GMAB) pays no dividend (payout 0.00%).
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
343.43%
- MRK
- 343.43%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GMAB | MRK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.29% |
| Dividend Payout Ratio (TTM) | 0.00% | 343.43% |
Valuation
P/E Ratio (TTM)
Both look expensive on trailing earnings: Genmab (GMAB) at 45.84 sits in the richer P/E ratio quartile, and Merck (MRK) at 148.21 is richer still, above its industry range.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
148.21
- MRK
- 148.21
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Genmab (GMAB) at 7.68 and Merck (MRK) at 5.37 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.37
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MRK
- 5.37
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Genmab (GMAB) at 5.36 is valued about in line with its industry on P/B ratio, while Merck (MRK) at 8.06 carries an above-peer premium to book — MRK is pricier on assets.
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.06
- Max
- 13.53
- MRK
- 8.06
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GMAB | MRK |
|---|---|---|
| P/E Ratio (TTM) | 45.84 | 148.21 |
| P/S Ratio (TTM) | 7.68 | 5.37 |
| P/B Ratio (MRQ) | 5.36 | 8.06 |
| Free Cash Flow Yield (TTM) | 2.59% | 3.88% |